<< Read Full Article
<< Read Full Article
The biotech sector saw a significant run-up last month, but for at least one analyst, questions remain about what the second half holds.
Mark Schoenebaum, a biotech analyst with Bear Stearns, cautioned Tuesday that on the basis of his research, he expects the sector's performance to be flat through the end of the year.
For the 20 trading days in July, biotech stock indices gained more than 10%. Among individual issues, Amgen (AMGN Quote) was up 31%, Genentech (DNA Quote) rose 10% and Genzyme (GENZ Quote) jumped 25%. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet